Business Standard

India unlikely to resume sizeable Covid vaccine exports until Oct: Report

Battling the world's biggest jump in coronavirus infections, India halted vaccine exports a month ago after donating or selling more than 66 million doses

Covishield
Premium

Employees pack boxes containing vials of AstraZeneca's Covishield vaccine at the Serum Institute of India, in Pune (Photo: AP/PTI)

Reuters New Delhi
India is unlikely to resume major exports of Covid-19 vaccines until at least October as it diverts shots for domestic use, three government sources said, a longer-than-expected delay set to worsen supply shortages from the global Covax initiative.

Battling the world's biggest jump in coronavirus infections, India halted vaccine exports a month ago after donating or selling more than 66 million doses. The move has left countries including Bangladesh, Nepal, Sri Lanka and many in Africa scrambling for alternate supplies.

The World Health Organization, which co-leads Covax, on Monday called on vaccine makers outside India to advance supplies to the

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in